How do you interpret efficacy of trastuzumab deruxtecan based on HER2 mutation type and/or level of HER2 overexpression?  

How and when do you plan to perform HER2 testing in patients with NSCLC?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution